Creatine in Women’s Health: Where the Research Actually Stands in 2026

Creatine is one of the most extensively studied supplements in sports nutrition, supported by hundreds of peer-reviewed publications. Much of that foundational evidence was generated in men, though female-only trials appeared as early as the mid-1990s.

The result is a field where the questions are uneven. Some are relatively well established, some remain contested, and one newly identified preclinical signal raises a question that has not yet been tested in supplement users.

How the field got here

Creatine research in women began with small performance trials. Early findings were mixed: a 1996 study in female swimmers found no benefit, while a 1997 resistance-training trial reported greater gains in strength, fat-free mass, and intermittent exercise capacity.

Research later expanded to older and postmenopausal women, with increasing attention to strength, lean mass, and physical function. A major conceptual shift came in 2016, when researchers proposed that reproductive hormones may influence creatine synthesis, transport, and creatine kinase activity.

More recent studies have begun paying closer attention to menstrual cycle phase, hormonal contraceptive use, and menopausal status. These improvements should help researchers understand not only whether creatine works in women, but when and for whom its effects may be greatest.

Best established: strength and lean mass with resistance training

This is the strongest area of female-specific evidence.

A 2026 meta-analysis of seven randomized trials involving 608 postmenopausal women found that creatine increased lean mass by an average of 0.37 kilograms and leg-press strength by 7.5 kilograms compared with placebo. Benefits were most apparent in studies combining at least 5 grams per day with resistance training.

These are modest average gains, but they may be meaningful when the goal is to preserve muscle, strength, and physical function with age. The findings also align with creatine’s broader resistance-training evidence base.

Results in younger and active women are more variable, with benefits reported in some strength, power, and repeated-effort outcomes but not others. Many of these studies were small or short, making it difficult to determine whether women respond differently from men or whether existing trials simply lacked sufficient power.

What the evidence supports: Creatine is a reasonable evidence-based addition for women doing resistance training. The strongest female-specific support is in older and postmenopausal women using approximately 5 grams per day alongside a structured training program.

New and unresolved: brain, sleep, mood

Creatine's potential benefits may extend beyond muscle. The brain also uses the creatine–phosphocreatine system to meet rapid energy demands, providing a plausible basis for effects on memory, sleep, and mood.

Cognition. A 2023 meta-analysis of 23 randomized trials found that creatine improved memory, particularly in older adults, although effects were inconsistent across other cognitive domains. In the small CONCRET-MENOPA trial, peri- and postmenopausal women receiving 1,500 milligrams of creatine hydrochloride showed improvements in reaction time and frontal brain creatine. The study was short and used a different formulation from standard creatine monohydrate, but it provides an encouraging women-specific signal.

Sleep. One placebo-controlled study found longer sleep duration in naturally menstruating women taking creatine, especially after resistance-training days. A separate uncontrolled study reported improved sleep quality in a small perimenopausal subgroup. These findings are too limited to position creatine as a sleep aid, but they suggest sleep is a credible area for further research.

Mood. In women with major depressive disorder, adding creatine monohydrate to escitalopram produced faster and greater symptom improvement than placebo augmentation. Smaller studies in adolescent females with treatment-resistant depression have reported similar signals. These results support a possible role alongside established treatment, but do not show that creatine improves everyday mood or menopause-related mood changes.

What the evidence suggests: Creatine has credible early signals for memory, sleep, and adjunctive depression treatment. These benefits are not yet established for women broadly, but the findings are promising enough to justify more targeted research.

Newly emerging but severely limited: perimenopause

Direct research in perimenopausal women was essentially absent until recently. That is now beginning to change.

CONCRET-MENOPA included women experiencing peri- and postmenopausal symptoms, while another 14-week study included a small perimenopausal subgroup. Early findings included changes in reaction time, brain creatine, and sleep, although most menopausal symptom outcomes were unchanged.

These studies are too small to establish creatine as a treatment for perimenopausal symptoms, but they provide a foundation for more targeted research.

What the evidence suggests: Creatine may have relevant applications during perimenopause, particularly for muscle and possibly brain-related outcomes, but direct symptom-specific claims are premature.

Contested: bone

Bone is where claims most clearly outpace the evidence.

The largest trial followed 237 postmenopausal women for two years and combined creatine with resistance training and walking. Creatine did not improve the primary outcome, femoral neck bone mineral density, or density at the hip or lumbar spine.

There were more favorable changes in some measures of bone geometry, which may matter because fracture risk depends on structure as well as density. However, these were secondary findings in a trial with a null primary outcome and have not been independently replicated. Meta-analyses in 2018 and 2026 likewise found no effect on bone density.

Status: Unresolved. Creatine may influence bone structure, but stronger trials with geometric outcomes specified in advance are needed.

An open question running the other direction: endometriosis

Most research asks where creatine might help women. Endometriosis research has raised the opposite possibility.

Two studies from the same laboratory found elevated creatine in endometriosis-related cells and reported that creatine may help lesions resist cell death, promote blood-vessel formation, and support fibrosis and cell migration.

The findings are preclinical and far from clinically established. The experiments used creatine concentrations much higher than physiological levels, the work has not been independently replicated, and no human study has tested whether supplementation changes creatine levels within endometriosis lesions or affects disease progression.

A separate observational study linking lower dietary creatine intake with hysterectomy and oophorectomy does not directly address endometriosis and cannot resolve the question.

Status: An intriguing laboratory signal with unclear relevance to oral supplementation. There is currently no basis for changing clinical guidance.

What is holding the field back

Small samples. Many widely discussed studies include only 15 to 40 participants, with subgroup findings sometimes based on fewer than ten women.

Weak designs. Some menopause-related findings come from uncontrolled studies, making it impossible to separate creatine’s effects from resistance training or changes over time.

Poor reporting of female physiology. In a 2025 review of 27 studies in active women, only three reported menstrual cycle information, one used appropriate terminology for menstrual and contraceptive status, and none provided fuller reproductive-status data. Randomization and blinding were also often poorly described.

Multiple testing. Studies that measure many outcomes increase the chance of false-positive findings unless primary outcomes are prespecified or statistical corrections are used. Some recent exploratory studies did neither.

Industry ties. Several recent reviews and trials disclose relationships with the same creatine manufacturer, including research support, advisory roles, patents, and company ownership. These ties do not invalidate the findings, but they make rigorous design and independent replication especially important.

What would move the field

Four things: a controlled perimenopause trial using monohydrate, with standardized staging, a placebo arm, and adequate power and duration; a bone trial powered on geometric endpoints as primary outcomes; dose-response work on brain creatine using monohydrate, since the dose needed for clinically meaningful cognitive effects is unknown; and work on whether oral supplementation alters peritoneal or lesion creatine metabolism, and whether that affects endometriosis outcomes.

Where that leaves things

For women who resistance train, creatine monohydrate is a well-supported option for modest additional gains in strength and lean mass. The evidence is strongest in older and postmenopausal women, but the broader creatine literature supports its use across adult age groups.

A practical evidence-based protocol remains straightforward: creatine monohydrate, typically 3 to 5 grams daily, taken consistently and paired with progressive resistance training. A loading phase is optional rather than necessary.

Research into cognition, sleep, mood, and perimenopause has produced enough positive findings to justify interest, but not enough to promise that every woman will experience these benefits. Bone-density findings have been largely neutral, while possible effects on bone structure remain under investigation. Endometriosis research is currently laboratory-based and does not establish a supplementation risk.

Overall, creatine deserves a slightly more supportive conclusion than much of the women-specific literature alone might suggest. It already has a credible role in supporting muscle and strength, and emerging research is testing whether its benefits extend to other areas of women’s health. The next phase is not about proving that creatine has no value for women. It is about defining the full extent of that value more precisely.